The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.

References

[1]Ritchie K, Carrière I, Ritchie CW, Berr C, Artero S, Ancelin ML. Can we design prevention programs to reduce dementia incidence? A prospective study of modifiable risk factors. BMJ. 2010; 341: 3885–3892
10.1136/bmj.c3885
CASPubMedWeb of Science®Google Scholar
[2]Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011; 10: 819–828
10.1016/S1474-4422(11)70072-2
PubMedWeb of Science®Google Scholar
[3]Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004; 101: 284–289
10.1073/pnas.2635903100
CASPubMedWeb of Science®Google Scholar
[4]Scarmeas N, Habeck CG, Stern Y, Anderson KE. APOE genotype and cerebral blood flow in healthy young individuals. JAMA. 2003; 290: 1581–1582
10.1001/jama.290.12.1581
CASPubMedWeb of Science®Google Scholar
[5]Alexopoulos P, Richter-Schmidinger T, Horn M, Maus S, Reichel M, Sidiropoulos C, et al. Hippocampal volume differences between healthy young Apolipoprotein E e2 and e4 carriers. J Alzheimers Dis. 2011; 26: 207–210
10.3233/JAD-2011-110356
CASPubMedWeb of Science®Google Scholar
[6]Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in Dominantly Inherited Alzheimer's Disease. N Engl J Med. 2012; 367: 795–804
10.1056/NEJMoa1202753
CASPubMedWeb of Science®Google Scholar
[7]Ritchie K, Ritchie CW, Yaffe K, Skoog I, Scarmeas N. Is Alzheimer's disease really a disease of mid-life. Alzheimers Dement (N Y). 2015; 1: 122–130
10.1016/j.trci.2015.06.004
Google Scholar
[8]Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S on behalf of the European Prevention of Alzheimer's Dementia (EPAD) Consortium. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry. 2016; 3: 179–186
10.1016/S2215-0366(15)00454-X
PubMedWeb of Science®Google Scholar
[9]Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9: 119–128
10.1016/S1474-4422(09)70299-6
CASPubMedWeb of Science®Google Scholar
[10]Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an up-dated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12: 207–216
10.1016/S1474-4422(12)70291-0
CASPubMedWeb of Science®Google Scholar
[11]Ritchie K, Carrière I, Berr C, Amieva H, Dartigues JF, Ancelin ML, et al. The clinical picture of Alzheimer's disease in the decade before diagnosis: clinical and biomarker trajectories. J Clin Psychiatry. 2016; 77: e305–e311
10.4088/JCP.15m09989
PubMedWeb of Science®Google Scholar
[12]Ritchie K, Kotzki PO, Touchon J, Cristol JP. Characterisitics of Alzheimer's disease patients with and without ApoE e4 allele. Lancet. 1996; 348: 960–961
10.1016/S0140-6736(05)65371-8
CASPubMedWeb of Science®Google Scholar
[13]Chen KH, Chuah LY, Sim SK, Chee MW. Hippocampal region-specific contributions to memory performance in normal elderly. Brain Cogn. 2010; 72: 400–407
10.1016/j.bandc.2009.11.007
PubMedWeb of Science®Google Scholar
[14]Nestor PJ, Fryer TD, Ikeda M, Hodges JR. Retrospelnia cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease). Eur J Neurosci. 2003; 18: 2663–2667
10.1046/j.1460-9568.2003.02999.x
CASPubMedWeb of Science®Google Scholar
[15]Rowe CC, Ng S, Ackerman U, Gong SJ, Pike K, Savage G. Imaging beta amyloid burden in aging and dementia. Neurology. 2007; 68: 1718–1725
10.1212/01.wnl.0000261919.22630.ea
CASPubMedWeb of Science®Google Scholar
[16]Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci. 2014; 17: 304–311
10.1038/nn.3606
CASPubMedWeb of Science®Google Scholar
[17]Moodley K, Minati L, Contarino V, Prioni S, Wood R, Cooper R, et al. Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependant test of spatial memory. Hippocampus. 2015; 25: 939–951
10.1002/hipo.22417
PubMedWeb of Science®Google Scholar
[18]Tu S, Wong S, Hodges JR, Irish M, Piguet O, Hornberger M. Lost in spatial translation – A novel tool to objectively assess spatial disorientation in Alzheimer's disease and frontotemporal dementia. Cortex. 2015; 67: 83–94
10.1016/j.cortex.2015.03.016
PubMedWeb of Science®Google Scholar
[19]Jungwirth S, Zehetmayer S, Bauer P, Weissgram S, Tragl KH, Fischer P. Prediction of Alzheimer dementia with short neuropsychological instruments. J Neural Transm (Vienna). 2009; 116: 1513–1521
10.1007/s00702-009-0318-6
PubMedWeb of Science®Google Scholar
[20]Amieva H, Jacqmin-Gadda H, Orgogozo JM, Le Carret N, Helmer C, Letenneur L. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population based study. Brain. 2005; 128: 1093–1101
10.1093/brain/awh451
PubMedWeb of Science®Google Scholar
[21]Laukka EJ, Macdonald SW, Fratiglioni L, Bäckman L. Preclinical cognitive trajectories differ for Alzheimer's disease and vascular dementia. J Int Neuropsychol Soc. 2012; 18: 191–199
10.1017/S1355617711001718
Google Scholar
[22]Rajan KB, Wilson RS, Weuve J, Barnes LL, Evans DA. Cognitive impairment 18 years before clinical diagnosis of Alzheimer's disease dementia. Neurology. 2015; 5: 1–8
Google Scholar
[23]Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012; 69: 223–229
10.1001/archneurol.2011.666
PubMedWeb of Science®Google Scholar
[24]Song Z, Insel PS, Buckley S, Yohannes S, Mezher A, Simonson A. Brain amyloid-beta burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly. J Neurosci. 2015; 35: 3240–3247
10.1523/JNEUROSCI.2092-14.2015
CASPubMedWeb of Science®Google Scholar
[25]Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid –cognition relations in cognitively normal adults. Neurology. 2013; 80: 1341–1348
10.1212/WNL.0b013e31828ab35d
CASPubMedWeb of Science®Google Scholar
[26]Bilgel M, An Y, Lang A, Prince J, Jedynak B, Resnick SM. Trajectories of AD-related cognitive measures in a longitudinal sample. Alzheimers Dement. 2014; 10: 735–742
10.1016/j.jalz.2014.04.520
PubMedWeb of Science®Google Scholar
[27]Yotter RA, Doshi J, Clark V, Sojkova J, Zhou Y, Wong DF, et al. Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. Neurobiol Aging. 2013; 34: 2835–2842
10.1016/j.neurobiolaging.2013.05.030
CASPubMedWeb of Science®Google Scholar
[28]Nutter-Upham KE, Saykin AJ, Rabin LA, Roth R, Wishart HA, Pare N, et al. Verbal fluency performance in amnestic MCI and older adults with cognitive complaints. Arch Clin Neuropsychol. 2008; 23: 229–241
10.1016/j.acn.2008.01.005
PubMedWeb of Science®Google Scholar
[29]Kennedy KM, Rodrigue KM, Devous MD, Hebrank AC, Bischof GN, Park DC. Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. Neuroimage. 2012; 62: 1–8
10.1016/j.neuroimage.2012.03.077
CASPubMedWeb of Science®Google Scholar
[30]Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive Decline in Prodromal Alzheimer Disease and Mild Cognitive Impairment. Arch Neurol. 2011; 68: 351–356
10.1001/archneurol.2011.31
PubMedWeb of Science®Google Scholar
[31]Duff K, Foster NL, Dennett K, Hammers DB, Zollinger LV, Christian PE, et al. Amyloid deposition and cognition in older adults: the effects of premorbid intellect. Arch Clin Neuropsychol. 2013; 28: 665–671
10.1093/arclin/act047
Google Scholar
[32]Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology. 2012; 79: 1636–1644
10.1212/WNL.0b013e3182661f74
CASPubMedWeb of Science®Google Scholar
[33]Kramer JH, Mungas D, Possin KL, Rankin KP, Boxer AL, Rosen HJ, et al. NIH EXAMINER: Conceptualization and Development of an Executive Function Battery. J Int Neuropsychol Soc. 2014; 20: 11–19
10.1017/S1355617713001094
PubMedWeb of Science®Google Scholar
[34]Rentza DM, Amariglioa RE, Becker JA, Freya M, Olsona LE, Frishea K, et al. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011; 49: 2776–2783
Google Scholar
[35]Grober E, Sanders AE, Hall C, Lipton RB. Free and cued selective reminding identifies very mild dementia in Primary Care. Alzheimer Dis Assoc Disord. 2010; 24: 284–290
10.1097/WAD.0b013e3181cfc78b
PubMedWeb of Science®Google Scholar
[36]Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, et al. Prodromal Alzheimer's Disease: Successive emergence of the clinical symptoms. Ann Neurol. 2008; 64: 492–498
10.1002/ana.21509
PubMedWeb of Science®Google Scholar
[37]Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc. 2008; 14: 266–278
10.1017/S1355617708080302
PubMedWeb of Science®Google Scholar
[38]Karantzoulis S, Novitski J, Gold M, Randolph C. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in Detection and Characterization of Mild Cognitive Impairment due to Alzheimer's Disease. Arch Clin Neuropsychol. 2013; 28: 837–844
10.1093/arclin/act057
Google Scholar
[39]England HB, Gillis MM, Hampstead BM. RBANS Memory indices are related to medial temporal lobe volumetrics in healthy older adults and those with mild cognitive impairment. Arch Clin Neuropsychol. 2014; 29: 322–328
10.1093/arclin/acu012
PubMedWeb of Science®Google Scholar
[40]Hampstead BH, Stringer AY, Stilla RF, Deshpande G, Hu X, Moore AB, et al. Activation and effective connectivity changes following explicit memory training for name-face pairs in patients with mild cognitive impairment: a pilot study. Neurorehabil Neural Repair. 2011; 25: 210–222
10.1177/1545968310382424
PubMedWeb of Science®Google Scholar
[41]Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging. 2015; 36: 1239–1244
10.1016/j.neurobiolaging.2014.12.008
CASPubMedWeb of Science®Google Scholar
[42]Ellis KA, Lima YY, Harrington K, Ames D, Bush AI, Darby D, et al. and the AIBL Research Group. Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-beta. J Alzheimers Dis. 2013; 34: 861–871
Google Scholar
[43]Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid peptide deposition identified with Pittsburgh Compound B. Arch Neurol. 2009; 66: 1476–1481
10.1001/archneurol.2009.272
PubMedWeb of Science®Google Scholar
[44]Ritchie K, deRoquefeuil G, Ritchie CW, Besset A, Poulain V, Artero S, et al. COGNITO: Computerized Assessment of Information Processing. J Psychol Psychother. 2014; 4: 136
Google Scholar
[45]Riley KP, Jicha GA, Davis D, Abner EL, Cooper GE, Stilese N, et al. Prediction of preclinical Alzheimer's Disease: longitudinal rates of change in cognition. J Alzheimers Dis. 2011; 25: 707–717
PubMedWeb of Science®Google Scholar

Citing Literature

Volume13, Issue2

February 2017

Pages 186-195

Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project

Abstract

References

Citing Literature

References

Related

Information